KI-301690 inhibits the expression of ECM components, including collagen, fibronectin, and vimentin, by blocking the DDR1/PYK2/FAK signaling pathway, significantly reducing tumor growth in a pancreatic xenograft model when combined with gemcitabine [117]. Here, PTK2 is linked to neoplasm.